Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inmune Bio (INMB) Total Non-Current Liabilities (2021 - 2023)

Inmune Bio (INMB) has disclosed Total Non-Current Liabilities for 3 consecutive years, with $17.2 million as the latest value for Q3 2023.

  • Quarterly Total Non-Current Liabilities changed N/A to $17.2 million in Q3 2023 from the year-ago period, while the trailing twelve-month figure was $17.2 million through Sep 2023, changed N/A year-over-year, with the annual reading at $21.1 million for FY2022, 7.21% up from the prior year.
  • Total Non-Current Liabilities hit $17.2 million in Q3 2023 for Inmune Bio, down from $21.1 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $21.1 million in Q4 2022 to a low of $17.2 million in Q3 2023.
  • Historically, Total Non-Current Liabilities has averaged $18.9 million across 3 years, with a median of $18.9 million in 2021.
  • Biggest YoY gain for Total Non-Current Liabilities was 7.21% in 2022; the steepest drop was 7.21% in 2022.
  • Year by year, Total Non-Current Liabilities stood at $19.7 million in 2021, then rose by 7.21% to $21.1 million in 2022, then fell by 18.82% to $17.2 million in 2023.
  • Business Quant data shows Total Non-Current Liabilities for INMB at $17.2 million in Q3 2023, $21.1 million in Q4 2022, and $18.7 million in Q1 2022.